Editas Medicine EDIT
NASDAQ EDIT
$2.62 +0.10 (+3.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

Editas Medicine (EDIT) Gains from Sales and Divestitures (2023 - 2024)

Updated

Editas Medicine (EDIT) reported Gains from Sales and Divestitures of -$10,000 for Q4 2024, compared with $1.58 million a year earlier.

Analysis

Editas Medicine (EDIT) Gains from Sales and Divestitures (2023 - 2024) Analysis & Trends

For FY2024, Editas Medicine posted Gains from Sales and Divestitures of -$149,000.

  • Five-year quarterly Gains from Sales and Divestitures spans a low of -$1.58 million in Q1 2023 and a high of $1.58 million in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Editas Medicine 244.35 Mn -467.41 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -10,000.00
Sep 30, 2024 -139,000.00
Dec 31, 2023 1.58 Mn
Mar 31, 2023 -1.58 Mn
API Access

Editas Medicine Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=EDIT&period=max&api_key=YOUR_API_KEY